Venus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 27 2024 - 4:05PM
Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ:
VERO), a global medical aesthetic technology leader, today
announced that it has closed its previously announced registered
direct offering priced at-the-market under Nasdaq rules for the
purchase and sale of 817,748 shares of common stock at a purchase
price of $1.465 per share. In a concurrent private placement, the
Company issued unregistered warrants to purchase up to 817,748
shares of common stock at an exercise price of $1.34 per share that
are immediately exercisable upon issuance and will expire five
years following the date of issuance.
H.C. Wainwright & Co. acted as the exclusive
placement agent for the offering.
The gross proceeds to the Company from the
offering were approximately $1.2 million, before deducting
placement agent fees and other offering expenses payable by the
Company. The Company intends to use the net proceeds from the
offering for general corporate purposes.
The common stock (but not the unregistered
warrants and the shares of common stock underlying the unregistered
warrants) described above were offered by the Company pursuant to a
“shelf” registration statement on Form S-3 (File No. 333-260267)
that was declared effective by the Securities and Exchange
Commission (the “SEC”) on October 25, 2021. The offering of the
shares of common stock was made only by means of a prospectus,
including a prospectus supplement, forming a part of the effective
registration statement. A final prospectus supplement and
accompanying prospectus relating to the registered direct offering
were filed with the SEC. Electronic copies of the final prospectus
supplement and accompanying prospectus may be obtained on the SEC’s
website at http://www.sec.gov or by contacting H.C. Wainwright
& Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York
10022, by phone at (212) 856-5711 or e-mail at
placements@hcwco.com.
The unregistered warrants described above were
issued in a private placement under Section 4(a)(2) of the
Securities Act of 1933, as amended (the “Securities Act”), and/or
Regulation D promulgated thereunder and, along with the shares of
common stock underlying such unregistered warrants, have not been
registered under the Securities Act, or applicable state securities
laws. Accordingly, the unregistered warrants and underlying shares
of common stock may not be offered or sold in the United States
except pursuant to an effective registration statement or an
applicable exemption from the registration requirements of the
Securities Act and such applicable state securities laws.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such jurisdiction.
About Venus Concept
Venus Concept is an innovative global medical
aesthetic technology leader with a broad product portfolio of
minimally invasive and non-invasive medical aesthetic and hair
restoration technologies and reach in over 60 countries and 12
direct markets. Venus Concept's product portfolio consists of
aesthetic device platforms, including Venus Versa, Venus Versa Pro,
Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow,
Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and
AI.ME. Venus Concept's hair restoration systems include NeoGraft®
and the ARTAS iX® Robotic Hair Restoration system. Venus Concept
has been backed by leading healthcare industry growth equity
investors including EW Healthcare Partners (formerly Essex
Woodlands), HealthQuest Capital, Longitude Capital Management,
Aperture Venture Partners, and Masters Special Situations.
Forward-Looking Statements
This communication contains “forward-looking”
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, including, without limitation, statements
about the Company’s financial condition, and other statements
containing the words “expect,” “intend,” “may,” “will,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on current expectations,
estimates, forecasts, and projections about the Company’s business
and the industry in which it operates and management’s beliefs and
assumptions and are not guarantees of future performance or
developments and involve known and unknown risks, uncertainties,
and other factors that are in some cases beyond the Company’s
control. Factors that could materially affect the Company’s
business operations and financial performance and condition
include, but are not limited to, the intended use of proceeds from
the offering, those risks and uncertainties described under Part I
Item 1A—“Risk Factors” in the Company’s most recent Annual Report
on Form 10-K, Part II Item 1A—“Risk Factors” in the Company’s most
recent Form 10-Q and in other documents the Company may file with
the SEC. You are urged to consider these factors carefully in
evaluating the forward-looking statements and are cautioned not to
place undue reliance on the forward-looking statements. The
forward-looking statements are based on information available to
the Company as of the date hereof. Unless required by law, the
Company does not intend to publicly update or revise any
forward-looking statements to reflect new information or future
events or otherwise.
Investor Relations Contact:
ICR Westwicke on behalf of Venus Concept:
Mike Piccinino, CFA
VenusConceptIR@westwicke.com
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Apr 2023 to Apr 2024